Horizon Therapeutics

Last updated
Horizon Therapeutics plc
FormerlyHorizon Pharma plc
Type Subsidiary
Nasdaq: HZNP
Industry Pharmaceutical
Founded2005;18 years ago (2005) [1]
Headquarters
Key people
Timothy P. Walbert (Chairman, President & CEO)

Paul W. Hoelscher (CFO)
Andy Pasternak (CBO)

Jeffrey W. Sherman, M.D. (CMO)
RevenueIncrease2.svg US$3.63 billion (2022)
Increase2.svg US$617 million (2022)
Decrease2.svg US$521 million (2022)
Total assets Increase2.svg US$9.11 billion (2022)
Total equity Increase2.svg US$5.07 billion (2022)
Number of employees
2,115 (2022)
Parent Amgen
Website horizontherapeutics.com
Footnotes /references
[2]

Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. [3] Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. [4] Amgen acquired the company in October 2023. [5]

Contents

History

In 2014, Horizon executed a tax inversion to move its legal headquarters to Ireland to avail itself of Ireland's low tax rates and beneficial corporate tax system. [6] [7]

In October 2014, the company acquired the US sales and marketing rights to the osteoarthritis drug Pennsaid from Nuvo Research for $45 million. [8]

In March 2015, the company acquired Hyperion Therapeutics for $1.1 billion, increasing Horizon's orphan disease drug portfolio. [9] In December, the company acquired Crealta Holdings for $510 million. [10]

In September 2016, the company announced the acquisition of Raptor Pharmaceutical for $800 million, adding Procysbi and Quinsair to its rare drug portfolio. [11]

In 2017, Horizon announced its intention to acquire River Vision Development Corp for $145 million and to continue the development of teprotumumab. [12]

On May 2, 2019, shareholders of the company approved the change of the company's name from Horizon Pharma plc to Horizon Therapeutics plc. [13]

In January 2020 – after showing very strong PhIII data – it was approved for the treatment of thyroid eye disease (TED), a rare vision-threatening disease that previously had no FDA-approved treatment options. [14] Horizon believed it could reach $1 billion peak sales in the US alone.

In February 2021, the business announced it would acquire Viela Bio Inc for around $3 billion ($53 per share). [15] [16]

In December 2022, the company announced it would be acquired by Amgen for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium). [17] The company was reportedly the center of a bidding war between Amgen, Johnson & Johnson and Sanofi. [18] In May 2023, the Federal Trade Commission said it would sue to block the deal in an attempt to control drug prices. [17] [19] [20] The acquisition was completed in October 2023 after mutually resolving the litigation. [5]

Horizon Therapeutics sales by region (2017) [4]
RegionSales ($ m)Distribution (%)
U.S.1,026.52797
Rest of World29.7043
Total1,056.231100

Activity

The company has cooperated with American Gastroenterological Association (AGA) Institute to launch a program named "Connect to Protect" which aims to help physicians and patients better understand non-steroidal anti-inflammatory drug (NSAID) risks. The program is planned to promote communications between physicians and patients about NSAIDs and gastrointestinal ulcers. [21]

In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). [22]

Operations and locations

In March 2014, the company executed a corporate tax inversion to Ireland by acquiring Irish–based Vidara Therapeutics International for $660 million. [23] While Horizon's main operations and sales remained in the U.S., Horizon moved their "legal" headquarters to Ireland to avoid U.S. taxes. [24] In July 2015, the Wall Street Journal noted that Horizon were using their lower Irish corporate tax rate to acquire further U.S.–based life sciences firms (i.e. Horizon could afford to pay more). [25]

In early 2022, the company signed a lease on a large research and development facility in Rockville, Maryland.

It is also expanding its development and manufacturing facility in Waterford (Ireland) for the production of rare disease biologics and drugs still in development. [26]

Therapeutic areas

Horizon's drug portfolio is focused on treatments for thyroid eye disease (TED), gout, rare diseases, and inflammatory diseases. [27] Horizon's portfolio includes Tepezza [18] (teprotumumab), Krystexxa (pegloticase), Actimmune (interferon gamma), Duexis (ibuprofen + famotidine), Pennsaid (diclofenac, 2% topical), Rayos/Lodotra (prednisone), Vimovo (naproxen/esomeprazole magnesium), Buphenyl (sodium phenylbutyrate), Procysbi (cysteamine bitartrate), and Ravicti (glycerol phenylbutyrate). [28]

Products

The company's lead product base includes Krystexxa, Duexis and Rayos. Outside the United States, Rayos is also known as Lodotra. [29]

See also

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc is an Anglo-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Perrigo</span> Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

<span class="mw-page-title-main">Actavis</span> Global pharmaceutical company

Actavis Generics is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

<span class="mw-page-title-main">Mallinckrodt</span> Irish domiciled pharmaceutical

Mallinckrodt Pharmaceuticals is an American-Irish domiciled manufacturer of specialty pharmaceuticals, generic drugs and imaging agents. In 2017, it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar was Medicaid's most expensive drug.

<span class="mw-page-title-main">Tax inversion</span> Corporate relocation to a lower tax location

A tax inversion or corporate tax inversion is a form of tax avoidance where a corporation restructures so that the current parent is replaced by a foreign parent, and the original parent company becomes a subsidiary of the foreign parent, thus moving its tax residence to the foreign country. Executives and operational headquarters can stay in the original country. The US definition requires that the original shareholders remain a majority control of the post-inverted company. In US federal legislation a company which has been restructured in this manner is referred to as an "inverted domestic corporation", and the term "corporate expatriate" is also used.

<span class="mw-page-title-main">National Organization for Rare Disorders</span> U.S. nonprofit organization

The National Organization for Rare Disorders (NORD) is an American non-profit organization aiming to provide support for individuals with rare diseases by advocating and funding research, education, and networking among service providers. It was founded in 1983 by Abbey Meyers, along with individuals and rare diseases leaders of rare disease support groups, and it is a 501(c)(3) tax exempt organization.

<span class="mw-page-title-main">Sumitomo Pharma</span> Pharmaceutical company based in Japan

Sumitomo Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

References

  1. ↑ "US Biopharma Firm Amgen To Acquire Horizon Therapeutics For $28 Bn". Barron's . Agence France-Presse. 12 December 2022.
  2. ↑ "Horizon Therapeutics Public Ltd Co 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 1 March 2023.
  3. ↑ "Amgen to buy Horizon Therapeutics in $26.4 billion deal". CNBC . Associated Press. 12 December 2022. Retrieved 18 June 2023.
  4. 1 2 "SEC Form 10-K: Horion Pharma public limited company". Securities and Exchange Commission. p. 89. Results of Operations: Net Sales
  5. 1 2 "Amgen completes $27.8 billion Horizon deal". Reuters. 6 October 2023.
  6. ↑ "Tracking Tax Runaways". Bloomberg News. 1 March 2017. Bloomberg Special Reports: Corporate Tax Inversions
  7. ↑ Vanessa Houlder; Vincent Boland; James Politi (29 April 2014). "Tax avoidance: The Irish inversion". Financial Times.
  8. ↑ "Horizon Pharma Picks Up Nuvo's Osteoarthritis Pain Drug Pennsaid 2% – GEN News Highlights – GEN". GEN.
  9. ↑ "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". GEN. 30 March 2015.
  10. ↑ "Horizon Pharma Buys Crealta Holdings for $510M". GEN. 11 December 2015. Retrieved 30 April 2016.
  11. ↑ "Horizon Pharma to Acquire Raptor for $800M – GEN". GEN. 12 September 2016. Retrieved 26 August 2017.
  12. ↑ "BRIEF-Horizon Pharma Plc to acquire River Vision Development Corp". Reuters. 8 May 2017. Retrieved 26 August 2017.
  13. ↑ "SEC Form 8-K: Horizon Therapeutics plc". 2 May 2019.
  14. ↑ "FDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)". Horizon Therapeutics. 21 January 2020. Retrieved 30 January 2020.
  15. ↑ "Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buy". Reuters. February 2021.
  16. ↑ Schere, Dan (6 January 2022). "Biopharmaceutical company signs lease for research and development facility in Rockville". Bethesda Beat . Retrieved 7 January 2022.
  17. 1 2 Mishra, Manas; Satija, Bhanvi (12 December 2022). "Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal". Reuters.
  18. 1 2 Kansteiner, Fraiser (2022-12-12). "Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war". Fierce Pharma. Retrieved 2023-01-26.
  19. ↑ Gilbert, Daniel (16 May 2023). "FTC sues to stop drugmaker Amgen from completing $27.8 billion deal". Washington Post . Retrieved 17 May 2023.
  20. ↑ Constantino, Annika Kim (2023-05-16). "FTC sues to block Amgen acquisition of Horizon Therapeutics". CNBC. Retrieved 2023-05-17.
  21. ↑ "Program introduction". ConnectToProtect.com. Retrieved 21 March 2014.
  22. ↑ "Teva wins controversial PhRMA bid despite protests from branded rivals – FiercePharma". www.FiercePharma.com. Retrieved 26 August 2017.
  23. ↑ "Horizon Pharma to Acquire Vidara Therapeutics International". Finance.yahoo.com. 19 March 2014. Retrieved 22 March 2014.
  24. ↑ Rubin, Ben Fox (19 March 2014). "Horizon Pharma to Acquire Vidara in $660 Million Deal". Wall Street Journal. Horizon Pharma Inc (NDAQ:HZNP) agreed to acquire Vidara Therapeutics Inc. in a cash-and-stock deal valued at about $660 million, as the specialty pharmaceutical company sought to expand its range of products. As part of the merger, the combined company will be named Horizon Pharma PLC and will be organized under the laws of Ireland. Horizon's current shareholders will own 74% of the merged company, and Vidara's shareholders will own about 26% of the company and receive $200 million in cash.
  25. ↑ Liz Hoffman (7 July 2015). "The Tax Inversion Wave Keeps Rolling". Wall Street Journal. Horizon and other inverted companies are using their new, lower tax rates to turbocharge corporate takeovers. Applying those rates, often in the midteens, to profits of companies in the U.S., with a federal corporate rate of 35%, can yield extra savings on top of those traditionally wrung from mergers. Moreover, unlike the U.S., Ireland and most other countries, only tax profits earned in-country, giving companies the freedom and incentive to shift income to still-lower-tax jurisdictions.
  26. ↑ Kansteiner, Fraiser (2022-08-29). "Horizon charts massive biologics expansion in Ireland, where it'll add 350 new jobs" . Retrieved 2023-05-31.
  27. ↑ "Horizon Therapeutics website: Our Portfolio page" . Retrieved 15 May 2020.
  28. ↑ "Horizon Therapeutics website: Our Portfolio page" . Retrieved 15 May 2020.
  29. ↑ "Marketwatch of Horizon Pharma Inc". Marketwatch.com. Retrieved 21 March 2014.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.